Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Creon 40,000 for Treatment of PEI (Pancreatic Exocrine Insufficiency) Due to Chronic Pancreatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00705978
Recruitment Status : Completed
First Posted : June 27, 2008
Last Update Posted : August 18, 2011
Information provided by:

Brief Summary:
This study will provide efficacy data for Creon 40,000 in CP subjects as well as long-term safety data. During the long-term treatment with Creon 40,000 nutritional parameters will be assessed and correlated with CFA.

Condition or disease Intervention/treatment Phase
Pancreatic Insufficiency Drug: Pancreatin Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 62 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A One Week Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study With Creon 40,000 MMS in Subjects With Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis, Followed by an Open-Label Long-Term Extension
Study Start Date : June 2008
Actual Primary Completion Date : May 2010
Actual Study Completion Date : May 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pancreatitis

Arm Intervention/treatment
Experimental: 1 Drug: Pancreatin
Pancreatin with 40000 lipase units per capsule, 2 capsules per main meal (3 main meals) plus 1 capsule per snack (2-3 snacks)

Placebo Comparator: 2 Drug: Placebo

Primary Outcome Measures :
  1. Change in CFA from baseline to the end of double blind treatment [ Time Frame: 7 days after baseline ]

Secondary Outcome Measures :
  1. CNA, stool fat, stool weight, nutritional, clinical symptomatology, SF-36, BMI [ Time Frame: 7 days after baseline, and end of open-label period (1 year of open label treatment) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Pancreatic exocrine insufficiency has to be proven (in medical history) by a pancreatic function test
  • Chronic pancreatitis has to be proven (in medical history) by CT, ERCP, plain film with pancreatic calcifications, ultrasonography (calcifications,duct dilatation) and /or histology
  • Females must be non-lactating and either be of non-childbearing potential or if of childbearing potential, agree to practice effective barrier contraceptive methods, use an intrauterine device (IUD) or use birth control pills or equivalent injectable contraceptive. The subject must have been practicing the selected method of birth control for at least 3 months prior to Visit 1 (Day -14).
  • Subjects with a pathological stool fat during run in period (> 10g/24 h)

Exclusion Criteria

  • Ileus or acute abdomen
  • Any type of malignancy involving the digestive tract in the last 5 years
  • Presence of pseudo pancreatic cysts >= 4 cm
  • Current excessive intake of alcohol or drug abuse
  • Hypersensitivity vs porcine proteins / pancreatin

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00705978

Layout table for location information
Site Reference ID/Investigator# 45389
Bangalore, India, 560017
Site Reference ID/Investigator# 45396
Bhopal, India, 462 016
Site Reference ID/Investigator# 45390
Chennai, India, 600096
Site Reference ID/Investigator# 54382
Cochin, India, 682304
Site Reference ID/Investigator# 45391
Hyderabad, India, 500082
Site Reference ID/Investigator# 45388
Jaipur, India, 302001
Site Reference ID/Investigator# 45387
Kolkatta, India, 700054
Site Reference ID/Investigator# 45383
Mumbai, India, 400012
Site Reference ID/Investigator# 45382
Pune, India, 411 004
Site Reference ID/Investigator# 45395
Pune, India, 411013
Site Reference ID/Investigator# 45393
Trivandrum, India, 695607
Sponsors and Collaborators
Abbott Products
Layout table for investigator information
Study Director: Guenter Krause, MD Abbott Products

Layout table for additonal information
Responsible Party: Gregor Eibes, Clinical Trial Manager, Abbott Products Identifier: NCT00705978    
Other Study ID Numbers: S245.4.009
First Posted: June 27, 2008    Key Record Dates
Last Update Posted: August 18, 2011
Last Verified: August 2011
Keywords provided by Abbott:
Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatitis, Chronic
Exocrine Pancreatic Insufficiency
Pancreatic Diseases
Digestive System Diseases
Gastrointestinal Agents